Compare ELPC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELPC | BIO |
|---|---|---|
| Founded | 1954 | 1952 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.3B |
| IPO Year | 1998 | 1994 |
| Metric | ELPC | BIO |
|---|---|---|
| Price | $10.06 | $360.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $16.20 | ★ $356.67 |
| AVG Volume (30 Days) | ★ 831.5K | 222.7K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | N/A | ★ 11.25 |
| Revenue | N/A | ★ $2,583,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.89 | $1.86 |
| P/E Ratio | $77.44 | ★ $32.66 |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $8.86 | $236.73 |
| 52 Week High | $14.51 | $396.23 |
| Indicator | ELPC | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.49 | 43.50 |
| Support Level | N/A | $350.89 |
| Resistance Level | $11.84 | $392.10 |
| Average True Range (ATR) | 0.23 | 12.70 |
| MACD | -0.01 | -1.89 |
| Stochastic Oscillator | 1.05 | 19.00 |
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power Sale, Services, and Holding. The majority of its revenue is generated from the Power distribution segment under which it provides public electricity distribution services, being responsible for the operation and maintenance of the distribution infrastructure, as well as providing related services.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.